Q-omics provides the consensus-scored OTUD6A profile across patient tissues and cancer cell-line models. OTUD6A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OTUD6A is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, OTUD6A RNA expression shows 7,128 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, BRCA, and TGCT as cancer lineages where OTUD6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD6A survival associations across molecular data types. OTUD6A RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD6A RNA expression–survival associations across cancer types. High OTUD6A expression shows unfavorable associations in UVM, KIRC, UCS, ACC and KICH, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for OTUD6A RNA expression.
This table summarizes OTUD6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OTUD6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD6A shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC. The BRCA box plot shows higher OTUD6A RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p = .012).
This table shows molecular features associated with OTUD6A in patient tissues and cancer cell lines. In patient samples, OTUD6A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
